

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

Art Unit: 1612

Aukunuru, Jithan et al.

Examiner: Basquill, Sean M

INTERNATIONAL APPLICATION NO: PCT/EP03/08005

FILED: July 22, 2003

U.S. APPLICATION NO: 10/521946

35 USC §371 DATE: January 21, 2005

FOR: Ophthalmic Ointment Composition Comprising a Drug, an Ointment
Base and a Solubilizing/Dispersing Agent

MS: Amendment

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed:

☒ Supplemental to the Information Disclosure Statement filed November 10, 2009.

If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to
Deposit Account No. 19-0134 in the name of Novartis.

☒ This Information Disclosure Statement is being filed in accordance with 37 C.F.R.
§1.97(c) or 37 C.F.R. §1.97(d).

☒ A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the
references cited on the attached form(s) PTO-1449.


☒ These references were cited in a search report in the corresponding PCT Application.
No. PCT/EP03/08005. Per Examiners request of February 26, 2009, copies of these
references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587

Date:

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864